Discovery of brain-penetrant, orally bioavailable aminothienopyridazine inhibitors of tau aggregation.
Agents capable of preventing the misfolding and sequestration of the microtubule-stabilizing protein tau into insoluble fibrillar aggregates hold considerable promise for the prevention and/or treatment of neurodegenerative tauopathies such as Alzheimer's disease. Because tauopathies are characterized by amyloidosis that is restricted to the central nervous system (CNS), plausible candidate compounds for in vivo evaluation must both prevent tau fibrillization and achieve significant brain levels. Recently, we reported the discovery of the aminothienopyridazine (ATPZ) class of tau aggregation inhibitors and now describe a series of new analogues that are both effective inhibitors of tau fibrillization and display significant brain-to-plasma exposure ratios after administration to mice. Further, two of the most promising examples, 15 and 16, were found to reach significant brain exposure levels following oral administration. Taken together, these results suggest that examples from the ATPZ class hold promise as candidates for in vivo efficacy studies in animal models of neurodegenerative tauopathies.
Ballatore
Carlo
C
Department of Chemistry, School of Arts and Sciences, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104-6323, USA. bcarlo@sas.upenn.edu
Brunden
Kurt R
KR
Piscitelli
Francesco
F
James
Michael J
MJ
Crowe
Alex
A
Yao
Yuemang
Y
Hyde
Edward
E
Trojanowski
John Q
JQ
Lee
Virginia M-Y
VM
Smith
Amos B
AB
D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D001812:Blood-Brain Barrier / Q000378:metabolism*; D055808:Drug Discovery; D051379:Mice; D055503:Protein Multimerization / Q000187:drug effects; D011724:Pyridazines / Q000493:pharmacokinetics*; D024801:Tauopathies / Q000188:drug therapy* / Q000517:prevention & control; D016875:tau Proteins / Q000187:drug effects*
D011724:Pyridazines; D016875:tau Proteins
J Med Chem. 2003 Sep 25;46(20):4265-72
13678405
Nat Rev Drug Discov. 2009 Oct;8(10):783-93
19794442
Biochemistry. 2009 Aug 18;48(32):7732-45
19580328
Annu Rev Neurosci. 2001;24:1121-59
11520930
Curr Alzheimer Res. 2005 Apr;2(2):219-26
15974921
Nat Rev Neurosci. 2007 Sep;8(9):663-72
17684513
Nat Rev Drug Discov. 2007 Jun;6(6):464-79
17541419
J Cell Biol. 1985 Nov;101(5 Pt 1):1799-807
2997236
NeuroRx. 2005 Jan;2(1):3-14
15717053
J Chemother. 2002 Oct;14(5):431-43
12462423
Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11213-8
8855335
J Biol Chem. 2005 Feb 4;280(5):3628-35
15525637
Exp Neurol. 2010 Jun;223(2):304-10
19744482
Biochemistry. 2007 Sep 4;46(35):10016-23
17685560
Curr Drug Metab. 2006 Feb;7(2):183-203
16472107
Biochemistry. 2004 Mar 16;43(10):2879-87
15005623
Angew Chem Int Ed Engl. 2007;46(48):9215-9
17985339
Biochem Biophys Res Commun. 2007 Jun 22;358(1):1-6
17482143
J Alzheimers Dis. 2008 Aug;14(4):393-9
18688089
Science. 1998 Dec 4;282(5395):1914-7
9836646
J Biol Chem. 2008 May 16;283(20):13806-16
18359772
J Biol Chem. 2005 Mar 4;280(9):7614-23
15611092
J Med Chem. 1979 Jan;22(1):48-52
423183
J Med Chem. 2008 Oct 9;51(19):6165-72
18771255
J Biol Chem. 2006 Jan 13;281(2):1205-14
16246844
Curr Alzheimer Res. 2007 Jul;4(3):315-23
17627489
NeuroRx. 2005 Oct;2(4):541-53
16489364
J Med Chem. 2009 Jun 11;52(11):3539-47
19432420